ClinicalTrials.gg
Active, not recruitingNCT02319837Updated Oct 26, 2026Results posted

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

A Phase 3 interventional study of Enzalutamide and Placebo (No longer applicable in Open Label study period) in Hormone Sensitive Prostate Cancer, Prostate Cancer and Cancer of the Prostate, sponsored by Pfizer. Active, not recruiting at 255 sites in 17 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Posted results revisedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,068
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
9th of 125
1,068 · median 52
Started
2014
with 22 others
Phase 3
16 of 125
1 open now
Primary completion
2023-01
later than 5 of 37 live
Registered
45th of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 9th largest by enrollment, is one of 23 that started in 2014, is one of 16 in phase 3, reaches primary completion later than 5 of the 37 other live ones, and was the 45th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.

The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study remains ongoing in open label format.

03

Conditions studied

  • Hormone Sensitive Prostate Cancer
  • Prostate Cancer
  • Cancer of the Prostate

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate at initial , without neuroendocrine differentiation, signet cell, or small cell features;
  • Prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent;
  • PSA doubling time ≤ 9 months;
  • Screening PSA by the central laboratory ≥ 1 ng/mL for patients who had radical prostatectomy (with or without radiotherapy) as primary treatment for prostate cancer and at least 2 ng/mL above the nadir for patients who had radiotherapy only as primary treatment for prostate cancer;
  • Serum testosterone ≥ 150 ng/dL (5.2 nmol/L).

Exclusion criteria

Exclusion Criteria:

  • Prior or present evidence of distant disease as assessed by radiographic imaging;
  • Prior hormonal therapy. /adjuvant therapy to treat prostate cancer ≤ 36 months in duration and ≥ 9 months before randomization, or a single dose or a short course (≤ 6 months) of hormonal therapy given for rising PSA ≥ 9 months before randomization is allowed.;
  • Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide for prostate cancer;
  • Prior systemic biologic therapy, including immunotherapy, for prostate cancer;
  • Major surgery within 4 weeks before randomization;
  • Treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks of randomization;
  • Known or suspected or active ;
  • History of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
1,068 participants (actual)

Study arms

  • Experimental
    Enzalutamide plus leuprolide

    Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as as a single intramuscular or subcutaneous injection once every 12 weeks

    Drug: Enzalutamide · Drug: Leuprolide Open Label

  • Experimental
    Enzalutamide monotherapy

    Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily

    Drug: Enzalutamide

  • Active comparator
    Leuprolide plus placebo

    Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks. The randomized blinded portion of the study has concluded following primary endpoint analyses. In the Open Label Period the placebo is no longer applicable in this study arm, and patients continue to receive leuprolide alone.

    Drug: Placebo (No longer applicable in Open Label study period)

Interventions

  • Also known as: MDV3100, Xtandi

  • DrugPlacebo (No longer applicable in Open Label study period)

    Sugar pill to mimic enzalutamide

  • Also known as: Eligard, Leuprolide Acetate, Leuprorelin, Lupron

06

What researchers measure

Primary outcomes

  1. Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide

    MFS was defined as the duration of time in months between randomization and the earliest objective evidence of radiographic progression by central imaging or death without radiographic progression, whichever occurred first. Radiographic progression for soft tissue disease was defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). Radiographic progression for bone disease was defined as the appearance of 1 or more metastatic lesions on bone scan (a bone scan assesses 5 regions of the skeleton, including skull, thorax, spine, pelvis, and extremities). Confirmation with a second imaging modality (plain film, computed tomography \[CT\], or magnetic resonance imaging \[MRI\]) was to be required when bone lesions were found in a single region on the bone scan. Appearance of metastatic lesions in 2 or more of the 5 regions on a bone scan was not to require confirmation with a second imaging modality.

    Time frame: From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)

Secondary outcomes

  1. Metastasis-free Survival (MFS) Compared Between Enzalutamide Monotherapy and Placebo Plus Leuprolide

    MFS was defined as the duration of time in months between randomization and the earliest objective evidence of radiographic progression by central imaging or death without radiographic progression, whichever occurred first. Radiographic progression for soft tissue disease was defined by RECIST 1.1. Radiographic progression for bone disease was defined as the appearance of 1 or more metastatic lesions on bone scan (a bone scan assesses 5 regions of the skeleton, including skull, thorax, spine, pelvis, and extremities). Confirmation with a second imaging modality (plain film, CT, or MRI) was to be required when bone lesions were found in a single region on the bone scan. Appearance of metastatic lesions in 2 or more of the 5 regions on a bone scan was not to require confirmation with a second imaging modality.

    Time frame: From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)

  2. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression was defined as the time in months from randomization to the date of the first PSA value demonstrating progression, while participants were on study treatment, which was subsequently confirmed at least 3 weeks later. PSA progression date was defined as the date that a ≥25% increase and an absolute increase of ≥2 micrograms per liter (μg/L) (2 nanograms per milliliter \[ng/mL\]) above the nadir (or baseline for participants with no PSA decline by Week 25) that was confirmed by a second consecutive value at least 3 weeks later. For participants who had suspended treatment at Week 37 and later reinitiated treatment, baseline was reset as the last PSA assessment prior to or on the date of reinitiation of treatment.

    Time frame: From randomization until first PSA progression (up to Month 98)

  3. Time to First Use of New Antineoplastic Therapy

    Time to first use of new antineoplastic therapy was defined as the time in months from randomization to first use of new antineoplastic therapy for prostate cancer.

    Time frame: From randomization until first use of new antineoplastic therapy (up to Month 98)

  4. Overall Survival (OS)

    Overall survival was defined as the time in months between randomization and death due to any cause.

    Time frame: From randomization until death due to any cause (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)

  5. Time to Distant Metastasis

    The time to distant metastasis was defined as the time in months from randomization to the earliest objective evidence of distant soft tissue metastases or metastatic bone disease by blinded independent central review (BICR).

    Time frame: From randomization until the earliest objective evidence of distant soft tissue metastases or metastatic bone disease (up to Month 98)

  6. Percentage of Participants With Undetectable Prostate-specific Antigen (PSA) at 36 Weeks on Study Drug

    Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. Percentage of participants with undetectable PSA at 36 weeks on study drug was calculated as the number of participants with undetectable PSA at Week 36 divided by the number of participants with PSA values at Week 36, and multiplied by 100.

    Time frame: At Week 36

  7. Percentage of Participants Who Remained Treatment-free 2 Years After Suspension of Study Treatment at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)

    Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. At Week 37, study treatment was suspended for participants whose PSA values were undetectable (\<0.2 ng/mL) at Week 36 as determined by the central laboratory. Study treatment may have been suspended only once (at Week 37) due to undetectable PSA and was reinitiated if subsequent central laboratory PSA values increased to ≥2.0 ng/mL for participants with prior prostatectomy or ≥5.0 ng/mL for participants without prostatectomy. Percentage of participants who remained treatment-free 2 years after suspension of study treatment at Week 37 was calculated as the number of participants who remained treatment-free 2 years after suspension of study treatment at Week 37 divided by the number of participants with treatment suspension and multiplied by 100.

    Time frame: From randomization until 2 years after Week 37 (up to Month 34)

  8. Percentage of Participants With Undetectable Prostate-specific Antigen (PSA) 2 Years After Suspension of Treatment at Week 37 Due to Undetectable PSA

    Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. At Week 37, study treatment was suspended for participants whose PSA values were undetectable (\<0.2 ng/mL) at Week 36 as determined by the central laboratory. Study treatment may have been suspended only once (at Week 37) due to undetectable PSA and was reinitiated if subsequent central laboratory PSA values increased to ≥2.0 ng/mL for participants with prior prostatectomy or ≥5.0 ng/mL for participants without prostatectomy. Percentage of participants with undetectable PSA 2 years after suspension of treatment at Week 37 due to undetectable PSA was calculated as the number of participants with undetectable PSA 2 years after suspension of treatment at Week 37 due to undetectable PSA divided by the number of participants with treatment suspension and multiplied by 100.

    Time frame: From randomization until 2 years after Week 37 (up to Month 34)

  9. Time to Resumption of Any Hormonal Therapy Following Suspension at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)

    Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. At Week 37, study treatment was suspended for participants whose PSA values were undetectable (\<0.2 ng/mL) at Week 36 as determined by the central laboratory. Study treatment may have been suspended only once (at Week 37) due to undetectable PSA and was reinitiated if subsequent central laboratory PSA values increased to ≥2.0 ng/mL for participants with prior prostatectomy or ≥5.0 ng/mL for participants without prostatectomy. The time to resumption of any hormonal therapy following suspension at Week 37 due to undetectable PSA was defined as the time in months between the date of treatment suspension at Week 37 due to undetectable PSA and the date that hormonal therapy was restarted.

    Time frame: From treatment suspension at Week 37 until resumption of any hormonal therapy (up to Month 98)

  10. Time to Castration Resistance

    Time to castration resistance applied only to participants receiving leuprolide treatment and was defined as the time in months from randomization to the first occurrence of radiographic disease progression by BICR, PSA progression or symptomatic skeletal event (SSE) whichever occurred first with castrate levels of testosterone (\<50 ng/dL).

    Time frame: From randomization to the first occurrence of radiographic disease progression, PSA progression or SSE, whichever occurred first with castrate levels of testosterone (up to Month 98)

  11. Time to Symptomatic Progression

    Time to symptomatic progression was defined as the time in months from randomization to development of a skeletal-related event, worsening of disease-related symptoms requiring initiation of a new antineoplastic therapy, or development of adverse events (AEs) and clinically significant signs and/or symptoms due to loco-regional tumor progression requiring opiate use, surgical intervention or radiation therapy, whichever occurred first.

    Time frame: From randomization until the first development of events defined as symptomatic progression (up to Month 98)

  12. Time to First Symptomatic Skeletal Event (SSE)

    Time to first symptomatic skeletal event was defined as the time in months from randomization to use of radiation therapy (external beam radiation therapy or radionuclides) or surgery to bone for prostate cancer, findings of clinically apparent pathologic bone fracture or of spinal cord compression, or new use of opiate and/or systemic antineoplastic therapy due to bone pain collected in the SSE case report form (CRF), whichever occurred first.

    Time frame: From randomization until the first development of events defined as SSE (up to Month 98)

  13. Time From Randomization to Onset of Clinically Relevant Pain Progression, Defined as a 2-point or Greater Increase From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Question 3 Score

    Time to clinically relevant pain progression was defined as the time from randomization to onset of pain progression, where clinically relevant pain progression was defined as a 2-point or greater increase from baseline in the BPI-SF question 3 score. BPI-SF is a self-administered questionnaire containing 9 main questions related to pain and analgesic medication use, where question 3 (paraphrased) is "On a scale of 0 \[no pain\] to 10 \[pain as bad as you can imagine\], please rate your pain at its worst in the last 24 hours" with higher score indicating worse pain.

    Time frame: From randomization until a 2-point or greater increase from baseline in the BPI-SF question 3 score (up to Month 98)

  14. Time From Randomization to First Assessment With at Least a 10-point Decline (Deterioration) From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score

    Time to first deterioration of the FACT-P total score was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the FACT-P total score. FACT-P total score is based on subscale scores of physical, social/family, emotional, and functional well-being, as well as 12 site-specific items to assess prostate-related symptoms, ranging 0-156, with higher score representing better quality of life.

    Time frame: From randomization to first assessment with at least a 10-point decrease from baseline in the FACT-P total score (up to Month 98)

  15. Number of Participants With Treatment-emergent Adverse Events (TEAEs) (All-causality) During On-treatment Period, Modified Treatment Period, and Treatment Reinitiation Period - at PCD Cut-off Date of 31 January 2023

    An AE was any untoward medical occurrence (eg, sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those events with onset dates occurring during the on-treatment period for the first time. On-treatment period was the time from the date of first dose of study treatment through a minimum of 30 days after last dose of study treatment, or the start day of new antineoplastic drug therapy minus 1 day. Modified TEAEs (mTEAEs) were AEs that occurred during the modified treatment period (events occurring or worsening during the treatment suspension period after 30 days of last dose prior to treatment suspension were excluded). Reinitiated TEAEs (rTEAEs) were AEs that occurred with a start date during the dosing period after suspension and reinitiation of study treatment as defined by the reinitiation treatment period.

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

  16. Number of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs) (All-causality) - at PCD Cut-off Date of 31 January 2023

    An AE was any untoward medical occurrence (e.g., sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those events with onset dates occurring during the on-treatment period for the first time. On-treatment period was defined as the time from the date of first dose of study treatment through a minimum of 30 days after last dose of study treatment, or the start day of new antineoplastic drug therapy minus 1 day. The severity of all TEAEs was evaluated by the investigator based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: grade 1 (mild), grade 2 (moderate), grade 3 (severe), grade 4 (potentially life-threatening) and grade 5 (death related to AE).

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

  17. Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Treatment-related) During On-treatment Period, Modified Treatment Period, and Treatment Reinitiation Period - at PCD Cut-off Date of 31 January 2023

    An AE was any untoward medical occurrence (eg, sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those with onset dates occurring during the on-treatment period for the first time. On-treatment period was the time from date of first dose of study treatment through at least 30 days after last dose of study treatment or start day of new antineoplastic drug therapy minus 1 day. Treatment-related TEAEs were TEAEs attributed to study drug (enzalutamide, placebo or leuprolide). mTEAEs were AEs that occurred during the modified treatment period (events occurring or worsening during the treatment suspension period after 30 days of last dose prior to treatment suspension were excluded). rTEAEs were AEs that occurred with a start date during the dosing period after suspension and reinitiation of study treatment (reinitiation treatment period).

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

  18. Number of Participants With SAEs (All-causality) During On-treatment Period, Modified Treatment Period and Treatment Reinitiation Period and SAEs (Treatment-related) During On-treatment period-at PCD Cut-off 31 Jan 2023

    An AE was any untoward medical occurrence in a participant administered study drug/other protocol-imposed intervention regardless of attribution. SAEs were AEs resulting in any of the following outcomes/deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. On-treatment period was time from first dose date of study treatment through ≥30 days after last dose of study treatment or start day of new antineoplastic drug therapy -1 day. mSAEs were SAEs occurring during modified treatment period (events occurring/worsening during treatment suspension period after 30 days of last dose prior to treatment suspension were excluded). rSAEs were SAEs occurring with a start date during the dosing period after suspension and reinitiation of study treatment. Treatment-related SAEs were attributed to any study drug.

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

  19. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Enzalutamide or Placebo Discontinuation - at PCD Cut-off Date of 31 January 2023

    An AE was any untoward medical occurrence (eg, sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those events with onset dates occurring during the on-treatment period for the first time. On-treatment period was the time from the date of first dose of study treatment through a minimum of 30 days after last dose of study treatment, or the start day of new antineoplastic drug therapy minus 1 day.

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

  20. Number of Participants With Shifts From Grade ≤2 at Baseline to Grade 3 or Grade 4 Post-baseline in Hematology Laboratory Test Values - at PCD Cut-off Date of 31 January 2023

    Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Hematology laboratory abnormalities were graded according to CTCAE version 4.03 (Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death). This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from ≤Grade 2 at baseline to Grade 3 and Grade 4 post-baseline for the following parameters: hemoglobin, leukocytes, lymphocytes, neutrophils, platelets.

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

  21. Number of Participants With Shifts From Grade ≤2 at Baseline to Grade 3 or Grade 4 Post-baseline in Chemistry Laboratory Test Values - at PCD Cut-off Date of 31 January 2023

    Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Chemistry laboratory abnormalities were graded according to CTCAE version 4.03 (Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death). This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from ≤Grade 2 at baseline to Grade 3 and Grade 4 post-baseline for the following parameters: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, calcium, creatine kinase, glucose, magnesium, phosphate, potassium, sodium.

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

  22. Number of Participants With Potentially Clinically Significant Vital Signs - at PCD Cut-off Date of 31 January 2023

    Participants with potentially clinically significant abnormalities in vital signs were summarized for the following parameters: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Potentially clinically significant abnormalities were defined as (1) SBP (mmHg): \>180 and increase from baseline \>40; \<90 and decrease from baseline \>30; final visit or 2 consecutive visits change from baseline (CFB) ≥10, ≥15, ≥20; final visit or most extreme result ≥140, ≥180, ≥140 and ≥20 CFB, ≥180 and ≥20 CFB; (2) DBP (mmHg): \>105 and increase from baseline \>30; \<50 and decrease from baseline \>20; final visit or 2 consecutive visits CFB ≥5, ≥10, ≥15; final visit or most extreme result ≥90, ≥105, ≥90 and ≥15 CFB, ≥105 and ≥15 CFB; (3) HR (bpm): \>120 and increase from baseline \>30; \<50 and decrease from baseline \>20.

    Time frame: From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

07

Results

Posted Mar 25, 2024

Participant flow

Study Treatment Phase
Participant flow — Study Treatment Phase
MilestoneEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Started355358355
Received treatment353354354
Completed000
Not completed355358355
Withdrew: Centrally confirmed radiographic progression266637
Withdrew: Psa progression notification from sponsor2205
Withdrew: Adverse event733663
Withdrew: Development of castration resistance020
Withdrew: Withdrawal by subject263225
Withdrew: Protocol violation221
Withdrew: Lost to follow-up010
Withdrew: Pi decision/disease progression by local conventional scan/psa, and other miscellaneous reasons174126
Withdrew: Other010
Withdrew: Ongoing; still in treatment phase as of primary completion date (pcd) cutoff date 31 jan 2023207153197
Withdrew: Participants did not receive treatment.241
Long-Term Follow-Up Phase
Participant flow — Long-Term Follow-Up Phase
MilestoneEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Started148205158
Completed000
Not completed148205158
Withdrew: Ongoing; participants still in long-time follow-up phase as of the pcd cutoff date (31 january 2023)6710462
Withdrew: Pi decision, site closure and other miscellaneous reasons5812
Withdrew: Withdrawal by subject403638
Withdrew: Lost to follow-up334
Withdrew: Death335442

Outcome measures

PrimaryMetastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide

MFS was defined as the duration of time in months between randomization and the earliest objective evidence of radiographic progression by central imaging or death without radiographic progression, whichever occurred first. Radiographic progression for soft tissue disease was defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). Radiographic progression for bone disease was defined as the appearance of 1 or more metastatic lesions on bone scan (a bone scan assesses 5 regions of the skeleton, including skull, thorax, spine, pelvis, and extremities). Confirmation with a second imaging modality (plain film, computed tomography \[CT\], or magnetic resonance imaging \[MRI\]) was to be required when bone lesions were found in a single region on the bone scan. Appearance of metastatic lesions in 2 or more of the 5 regions on a bone scan was not to require confirmation with a second imaging modality.

Time frame:
From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)
Reported as:
Median · Months
Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide
MonthsEnzalutamide + LeuprolidePlacebo + Leuprolide
Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus LeuprolideNA (NA to NA)NA (85.1 to NA)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = <0.0001 (Statistical significance can be declared if p-value \<0.05.) · Hazard ratio (hr): 0.424 · 95% CI 0.296 to 0.607
SecondaryMetastasis-free Survival (MFS) Compared Between Enzalutamide Monotherapy and Placebo Plus Leuprolide

MFS was defined as the duration of time in months between randomization and the earliest objective evidence of radiographic progression by central imaging or death without radiographic progression, whichever occurred first. Radiographic progression for soft tissue disease was defined by RECIST 1.1. Radiographic progression for bone disease was defined as the appearance of 1 or more metastatic lesions on bone scan (a bone scan assesses 5 regions of the skeleton, including skull, thorax, spine, pelvis, and extremities). Confirmation with a second imaging modality (plain film, CT, or MRI) was to be required when bone lesions were found in a single region on the bone scan. Appearance of metastatic lesions in 2 or more of the 5 regions on a bone scan was not to require confirmation with a second imaging modality.

Time frame:
From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)
Reported as:
Median · Months
Metastasis-free Survival (MFS) Compared Between Enzalutamide Monotherapy and Placebo Plus Leuprolide
MonthsEnzalutamide MonotherapyPlacebo + Leuprolide
Metastasis-free Survival (MFS) Compared Between Enzalutamide Monotherapy and Placebo Plus LeuprolideNA (NA to NA)NA (85.1 to NA)
Statistical analysis
  • Enzalutamide Monotherapy vs Placebo + Leuprolide · Log Rank · p = 0.0049 (Statistical significance can be declared if p-value \<0.03.) · Hazard ratio (hr): 0.631 · 95% CI 0.456 to 0.871
SecondaryTime to Prostate-specific Antigen (PSA) Progression

Time to PSA progression was defined as the time in months from randomization to the date of the first PSA value demonstrating progression, while participants were on study treatment, which was subsequently confirmed at least 3 weeks later. PSA progression date was defined as the date that a ≥25% increase and an absolute increase of ≥2 micrograms per liter (μg/L) (2 nanograms per milliliter \[ng/mL\]) above the nadir (or baseline for participants with no PSA decline by Week 25) that was confirmed by a second consecutive value at least 3 weeks later. For participants who had suspended treatment at Week 37 and later reinitiated treatment, baseline was reset as the last PSA assessment prior to or on the date of reinitiation of treatment.

Time frame:
From randomization until first PSA progression (up to Month 98)
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time to Prostate-specific Antigen (PSA) ProgressionNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = <0.0001 (Statistical significance can be declared if p-value \<0.02.) · Hazard ratio (hr): 0.068 · 95% CI 0.033 to 0.141
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = <0.0001 (Statistical significance can be declared if p-value \<0.03.) · Hazard ratio (hr): 0.331 · 95% CI 0.226 to 0.486
SecondaryTime to First Use of New Antineoplastic Therapy

Time to first use of new antineoplastic therapy was defined as the time in months from randomization to first use of new antineoplastic therapy for prostate cancer.

Time frame:
From randomization until first use of new antineoplastic therapy (up to Month 98)
Reported as:
Median · Months
Time to First Use of New Antineoplastic Therapy
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time to First Use of New Antineoplastic TherapyNA (NA to NA)76.2 (71.3 to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = <0.0001 (Statistical significance can be declared if p-value \<0.02.) · Hazard ratio (hr): 0.358 · 95% CI 0.263 to 0.488
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = <0.0001 (Statistical significance can be declared if p-value \<0.03.) · Hazard ratio (hr): 0.540 · 95% CI 0.411 to 0.709
SecondaryOverall Survival (OS)

Overall survival was defined as the time in months between randomization and death due to any cause.

Time frame:
From randomization until death due to any cause (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)

Results for this outcome have not been posted.

SecondaryTime to Distant Metastasis

The time to distant metastasis was defined as the time in months from randomization to the earliest objective evidence of distant soft tissue metastases or metastatic bone disease by blinded independent central review (BICR).

Time frame:
From randomization until the earliest objective evidence of distant soft tissue metastases or metastatic bone disease (up to Month 98)
Reported as:
Median · Months
Time to Distant Metastasis
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time to Distant MetastasisNA (NA to NA)NA (85.1 to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.443 · 95% CI 0.284 to 0.690
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = 0.0171 · Hazard ratio (hr): 0.614 · 95% CI 0.409 to 0.920
SecondaryPercentage of Participants With Undetectable Prostate-specific Antigen (PSA) at 36 Weeks on Study Drug

Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. Percentage of participants with undetectable PSA at 36 weeks on study drug was calculated as the number of participants with undetectable PSA at Week 36 divided by the number of participants with PSA values at Week 36, and multiplied by 100.

Time frame:
At Week 36
Reported as:
Number · Percentage of participants
Percentage of Participants With Undetectable Prostate-specific Antigen (PSA) at 36 Weeks on Study Drug
Percentage of participantsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Percentage of Participants With Undetectable Prostate-specific Antigen (PSA) at 36 Weeks on Study Drug97.3 (94.9 to 98.7)71.4 (66.3 to 76.2)90.2 (86.5 to 93.2)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSA doubling time, and prior hormonal therapy.) · Difference of percentage of participants: 25.9 · 95% CI 20.7 to 31.0
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSA doubling time, and prior hormonal therapy.) · Difference of percentage of participants: 18.8 · 95% CI 13.0 to 24.6
SecondaryPercentage of Participants Who Remained Treatment-free 2 Years After Suspension of Study Treatment at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)

Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. At Week 37, study treatment was suspended for participants whose PSA values were undetectable (\<0.2 ng/mL) at Week 36 as determined by the central laboratory. Study treatment may have been suspended only once (at Week 37) due to undetectable PSA and was reinitiated if subsequent central laboratory PSA values increased to ≥2.0 ng/mL for participants with prior prostatectomy or ≥5.0 ng/mL for participants without prostatectomy. Percentage of participants who remained treatment-free 2 years after suspension of study treatment at Week 37 was calculated as the number of participants who remained treatment-free 2 years after suspension of study treatment at Week 37 divided by the number of participants with treatment suspension and multiplied by 100.

Time frame:
From randomization until 2 years after Week 37 (up to Month 34)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Remained Treatment-free 2 Years After Suspension of Study Treatment at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)
Percentage of participantsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Percentage of Participants Who Remained Treatment-free 2 Years After Suspension of Study Treatment at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)34.6 (29.4 to 40.1)27.1 (21.6 to 33.2)14.1 (10.4 to 18.6)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Cochran-Mantel-Haenszel · p = 0.0439 (P-value was based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSA doubling time, and prior hormonal therapy.) · Difference of percentage of participants: 7.5 · 95% CI -0.2 to 15.2
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Cochran-Mantel-Haenszel · p = 0.0004 (P-value was based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSA doubling time, and prior hormonal therapy.) · Difference of percentage of participants: -12.9 · 95% CI -19.8 to -6.1
SecondaryPercentage of Participants With Undetectable Prostate-specific Antigen (PSA) 2 Years After Suspension of Treatment at Week 37 Due to Undetectable PSA

Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. At Week 37, study treatment was suspended for participants whose PSA values were undetectable (\<0.2 ng/mL) at Week 36 as determined by the central laboratory. Study treatment may have been suspended only once (at Week 37) due to undetectable PSA and was reinitiated if subsequent central laboratory PSA values increased to ≥2.0 ng/mL for participants with prior prostatectomy or ≥5.0 ng/mL for participants without prostatectomy. Percentage of participants with undetectable PSA 2 years after suspension of treatment at Week 37 due to undetectable PSA was calculated as the number of participants with undetectable PSA 2 years after suspension of treatment at Week 37 due to undetectable PSA divided by the number of participants with treatment suspension and multiplied by 100.

Time frame:
From randomization until 2 years after Week 37 (up to Month 34)
Reported as:
Number · Percentage of participants
Percentage of Participants With Undetectable Prostate-specific Antigen (PSA) 2 Years After Suspension of Treatment at Week 37 Due to Undetectable PSA
Percentage of participantsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Percentage of Participants With Undetectable Prostate-specific Antigen (PSA) 2 Years After Suspension of Treatment at Week 37 Due to Undetectable PSA16.8 (12.9 to 21.4)9.6 (6.2 to 14.0)4.6 (2.5 to 7.6)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Cochran-Mantel-Haenszel · p = 0.0089 (P-value was based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSA doubling time, and prior hormonal therapy.) · Difference of percentage of participants: 7.2 · 95% CI 1.7 to 12.8
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Cochran-Mantel-Haenszel · p = 0.0326 (P-value was based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSA doubling time, and prior hormonal therapy.) · Difference of percentage of participants: -5.0 · 95% CI -9.4 to -0.6
SecondaryTime to Resumption of Any Hormonal Therapy Following Suspension at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)

Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. At Week 37, study treatment was suspended for participants whose PSA values were undetectable (\<0.2 ng/mL) at Week 36 as determined by the central laboratory. Study treatment may have been suspended only once (at Week 37) due to undetectable PSA and was reinitiated if subsequent central laboratory PSA values increased to ≥2.0 ng/mL for participants with prior prostatectomy or ≥5.0 ng/mL for participants without prostatectomy. The time to resumption of any hormonal therapy following suspension at Week 37 due to undetectable PSA was defined as the time in months between the date of treatment suspension at Week 37 due to undetectable PSA and the date that hormonal therapy was restarted.

Time frame:
From treatment suspension at Week 37 until resumption of any hormonal therapy (up to Month 98)
Reported as:
Median · Months
Time to Resumption of Any Hormonal Therapy Following Suspension at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time to Resumption of Any Hormonal Therapy Following Suspension at Week 37 Due to Undetectable Prostate-specific Antigen (PSA)19.6 (17.2 to 22.3)16.8 (14.3 to 17.1)10.5 (8.9 to 11.5)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.693 · 95% CI 0.577 to 0.834
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 1.655 · 95% CI 1.381 to 1.984
SecondaryTime to Castration Resistance

Time to castration resistance applied only to participants receiving leuprolide treatment and was defined as the time in months from randomization to the first occurrence of radiographic disease progression by BICR, PSA progression or symptomatic skeletal event (SSE) whichever occurred first with castrate levels of testosterone (\<50 ng/dL).

Time frame:
From randomization to the first occurrence of radiographic disease progression, PSA progression or SSE, whichever occurred first with castrate levels of testosterone (up to Month 98)
Reported as:
Median · Months
Time to Castration Resistance
MonthsEnzalutamide + LeuprolidePlacebo + Leuprolide
Time to Castration ResistanceNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.090 · 95% CI 0.051 to 0.157
SecondaryTime to Symptomatic Progression

Time to symptomatic progression was defined as the time in months from randomization to development of a skeletal-related event, worsening of disease-related symptoms requiring initiation of a new antineoplastic therapy, or development of adverse events (AEs) and clinically significant signs and/or symptoms due to loco-regional tumor progression requiring opiate use, surgical intervention or radiation therapy, whichever occurred first.

Time frame:
From randomization until the first development of events defined as symptomatic progression (up to Month 98)
Reported as:
Median · Months
Time to Symptomatic Progression
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time to Symptomatic ProgressionNA (NA to NA)63.8 (56.4 to 74.9)NA (83.6 to NA)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.546 · 95% CI 0.427 to 0.699
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.619 · 95% CI 0.488 to 0.785
SecondaryTime to First Symptomatic Skeletal Event (SSE)

Time to first symptomatic skeletal event was defined as the time in months from randomization to use of radiation therapy (external beam radiation therapy or radionuclides) or surgery to bone for prostate cancer, findings of clinically apparent pathologic bone fracture or of spinal cord compression, or new use of opiate and/or systemic antineoplastic therapy due to bone pain collected in the SSE case report form (CRF), whichever occurred first.

Time frame:
From randomization until the first development of events defined as SSE (up to Month 98)
Reported as:
Median · Months
Time to First Symptomatic Skeletal Event (SSE)
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time to First Symptomatic Skeletal Event (SSE)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.261 · 95% CI 0.125 to 0.548
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = 0.0057 · Hazard ratio (hr): 0.423 · 95% CI 0.226 to 0.794
SecondaryTime From Randomization to Onset of Clinically Relevant Pain Progression, Defined as a 2-point or Greater Increase From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Question 3 Score

Time to clinically relevant pain progression was defined as the time from randomization to onset of pain progression, where clinically relevant pain progression was defined as a 2-point or greater increase from baseline in the BPI-SF question 3 score. BPI-SF is a self-administered questionnaire containing 9 main questions related to pain and analgesic medication use, where question 3 (paraphrased) is "On a scale of 0 \[no pain\] to 10 \[pain as bad as you can imagine\], please rate your pain at its worst in the last 24 hours" with higher score indicating worse pain.

Time frame:
From randomization until a 2-point or greater increase from baseline in the BPI-SF question 3 score (up to Month 98)
Reported as:
Median · Months
Time From Randomization to Onset of Clinically Relevant Pain Progression, Defined as a 2-point or Greater Increase From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Question 3 Score
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time From Randomization to Onset of Clinically Relevant Pain Progression, Defined as a 2-point or Greater Increase From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Question 3 Score13.9 (11.9 to 19.4)19.4 (13.8 to 24.9)16.6 (12.3 to 19.4)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = 0.4321 · Hazard ratio (hr): 1.078 · 95% CI 0.894 to 1.301
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = 0.3702 · Hazard ratio (hr): 1.090 · 95% CI 0.904 to 1.314
SecondaryTime From Randomization to First Assessment With at Least a 10-point Decline (Deterioration) From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score

Time to first deterioration of the FACT-P total score was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the FACT-P total score. FACT-P total score is based on subscale scores of physical, social/family, emotional, and functional well-being, as well as 12 site-specific items to assess prostate-related symptoms, ranging 0-156, with higher score representing better quality of life.

Time frame:
From randomization to first assessment with at least a 10-point decrease from baseline in the FACT-P total score (up to Month 98)
Reported as:
Median · Months
Time From Randomization to First Assessment With at Least a 10-point Decline (Deterioration) From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score
MonthsEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Time From Randomization to First Assessment With at Least a 10-point Decline (Deterioration) From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score8.3 (5.7 to 11.1)11.1 (8.3 to 14.0)8.4 (5.8 to 13.0)
Statistical analysis
  • Enzalutamide + Leuprolide vs Placebo + Leuprolide · Log Rank · p = 0.1567 · Hazard ratio (hr): 1.138 · 95% CI 0.954 to 1.357
  • Placebo + Leuprolide vs Enzalutamide Monotherapy · Log Rank · p = 0.0855 · Hazard ratio (hr): 1.168 · 95% CI 0.981 to 1.391
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) (All-causality) During On-treatment Period, Modified Treatment Period, and Treatment Reinitiation Period - at PCD Cut-off Date of 31 January 2023

An AE was any untoward medical occurrence (eg, sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those events with onset dates occurring during the on-treatment period for the first time. On-treatment period was the time from the date of first dose of study treatment through a minimum of 30 days after last dose of study treatment, or the start day of new antineoplastic drug therapy minus 1 day. Modified TEAEs (mTEAEs) were AEs that occurred during the modified treatment period (events occurring or worsening during the treatment suspension period after 30 days of last dose prior to treatment suspension were excluded). Reinitiated TEAEs (rTEAEs) were AEs that occurred with a start date during the dosing period after suspension and reinitiation of study treatment as defined by the reinitiation treatment period.

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs) (All-causality) - at PCD Cut-off Date of 31 January 2023

An AE was any untoward medical occurrence (e.g., sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those events with onset dates occurring during the on-treatment period for the first time. On-treatment period was defined as the time from the date of first dose of study treatment through a minimum of 30 days after last dose of study treatment, or the start day of new antineoplastic drug therapy minus 1 day. The severity of all TEAEs was evaluated by the investigator based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: grade 1 (mild), grade 2 (moderate), grade 3 (severe), grade 4 (potentially life-threatening) and grade 5 (death related to AE).

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) (Treatment-related) During On-treatment Period, Modified Treatment Period, and Treatment Reinitiation Period - at PCD Cut-off Date of 31 January 2023

An AE was any untoward medical occurrence (eg, sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those with onset dates occurring during the on-treatment period for the first time. On-treatment period was the time from date of first dose of study treatment through at least 30 days after last dose of study treatment or start day of new antineoplastic drug therapy minus 1 day. Treatment-related TEAEs were TEAEs attributed to study drug (enzalutamide, placebo or leuprolide). mTEAEs were AEs that occurred during the modified treatment period (events occurring or worsening during the treatment suspension period after 30 days of last dose prior to treatment suspension were excluded). rTEAEs were AEs that occurred with a start date during the dosing period after suspension and reinitiation of study treatment (reinitiation treatment period).

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

SecondaryNumber of Participants With SAEs (All-causality) During On-treatment Period, Modified Treatment Period and Treatment Reinitiation Period and SAEs (Treatment-related) During On-treatment period-at PCD Cut-off 31 Jan 2023

An AE was any untoward medical occurrence in a participant administered study drug/other protocol-imposed intervention regardless of attribution. SAEs were AEs resulting in any of the following outcomes/deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. On-treatment period was time from first dose date of study treatment through ≥30 days after last dose of study treatment or start day of new antineoplastic drug therapy -1 day. mSAEs were SAEs occurring during modified treatment period (events occurring/worsening during treatment suspension period after 30 days of last dose prior to treatment suspension were excluded). rSAEs were SAEs occurring with a start date during the dosing period after suspension and reinitiation of study treatment. Treatment-related SAEs were attributed to any study drug.

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Enzalutamide or Placebo Discontinuation - at PCD Cut-off Date of 31 January 2023

An AE was any untoward medical occurrence (eg, sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. TEAEs were those events with onset dates occurring during the on-treatment period for the first time. On-treatment period was the time from the date of first dose of study treatment through a minimum of 30 days after last dose of study treatment, or the start day of new antineoplastic drug therapy minus 1 day.

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Shifts From Grade ≤2 at Baseline to Grade 3 or Grade 4 Post-baseline in Hematology Laboratory Test Values - at PCD Cut-off Date of 31 January 2023

Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Hematology laboratory abnormalities were graded according to CTCAE version 4.03 (Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death). This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from ≤Grade 2 at baseline to Grade 3 and Grade 4 post-baseline for the following parameters: hemoglobin, leukocytes, lymphocytes, neutrophils, platelets.

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Shifts From Grade ≤2 at Baseline to Grade 3 or Grade 4 Post-baseline in Chemistry Laboratory Test Values - at PCD Cut-off Date of 31 January 2023

Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Chemistry laboratory abnormalities were graded according to CTCAE version 4.03 (Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death). This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from ≤Grade 2 at baseline to Grade 3 and Grade 4 post-baseline for the following parameters: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, calcium, creatine kinase, glucose, magnesium, phosphate, potassium, sodium.

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Potentially Clinically Significant Vital Signs - at PCD Cut-off Date of 31 January 2023

Participants with potentially clinically significant abnormalities in vital signs were summarized for the following parameters: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Potentially clinically significant abnormalities were defined as (1) SBP (mmHg): \>180 and increase from baseline \>40; \<90 and decrease from baseline \>30; final visit or 2 consecutive visits change from baseline (CFB) ≥10, ≥15, ≥20; final visit or most extreme result ≥140, ≥180, ≥140 and ≥20 CFB, ≥180 and ≥20 CFB; (2) DBP (mmHg): \>105 and increase from baseline \>30; \<50 and decrease from baseline \>20; final visit or 2 consecutive visits CFB ≥5, ≥10, ≥15; final visit or most extreme result ≥90, ≥105, ≥90 and ≥15 CFB, ≥105 and ≥15 CFB; (3) HR (bpm): \>120 and increase from baseline \>30; \<50 and decrease from baseline \>20.

Time frame:
From first dose of study drug to the last dose + 30 days, or the day before initiation of a new antineoplastic treatment (up to Month 98)

Results for this outcome have not been posted.

Adverse events

Collected over The treatment-emergent safety reporting period was from the first dose of study treatment on Day 1 through a minimum of 30 days after the last dose of study treatment, or the start day of new antineoplastic drug therapy minus 1 day (up to 98 months). For all-cause mortality, deaths as of the PCD data cutoff include deaths occuring during and after the treatment-emergent safety reporting period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide + Leuprolide33/355 (9.3%)123/353 (34.8%)339/353 (96%)
Placebo + Leuprolide55/358 (15.4%)112/354 (31.6%)341/354 (96.3%)
Enzalutamide Monotherapy42/355 (11.8%)131/354 (37%)345/354 (97.5%)
Most frequent serious events
Showing 10 of 339
Most frequent serious events
EventEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
SyncopeNervous system disorders9/3534/3542/354
PneumoniaInfections and infestations8/3534/3545/354
OsteoarthritisMusculoskeletal and connective tissue disorders8/3533/3542/354
HaematuriaRenal and urinary disorders8/3534/3548/354
Coronary artery diseaseCardiac disorders2/3531/3548/354
SepsisInfections and infestations4/3534/3546/354
ArthralgiaMusculoskeletal and connective tissue disorders5/3531/3541/354
Myocardial infarctionCardiac disorders3/3532/3545/354
Urinary tract infectionInfections and infestations2/3532/3545/354
FallInjury, poisoning and procedural complications3/3532/3545/354
Most frequent other events
Showing 10 of 51
Most frequent other events
EventEnzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide Monotherapy
Hot flushVascular disorders243/353203/35477/354
FatigueGENERAL DISORDERS151/353116/354165/354
GynaecomastiaReproductive system and breast disorders29/35332/354159/354
ArthralgiaMusculoskeletal and connective tissue disorders97/35374/35480/354
HypertensionVascular disorders82/35369/35467/354
FallInjury, poisoning and procedural complications72/35350/35452/354
Back painMusculoskeletal and connective tissue disorders60/35354/35461/354
Nipple painReproductive system and breast disorders11/3534/35454/354
NauseaGastrointestinal disorders42/35329/35453/354
Breast tendernessReproductive system and breast disorders5/3534/35451/354

Baseline characteristics

Baseline analysis population included all enrolled participants who received treatment.

Age, Continuous
Age, Continuous(years)Enzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide MonotherapyTotal
Mean69.1 ± 6.4969.1 ± 7.3369.1 ± 7.6669.1 ± 7.17
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide MonotherapyTotal
Female0000
Male3533543541061
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enzalutamide + LeuprolidePlacebo + LeuprolideEnzalutamide MonotherapyTotal
American Indian or Alaska Native4105
Asian26262678
Native Hawaiian or Other Pacific Islander1001
Black or African American16161547
White291298294883
More than one race2349
Unknown or Not Reported13101538
08

Study locations

255 sites

Showing the first 100 of 255 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Freedland SJ, De Giorgi U. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice. Future Oncol. 2026 Jun;22(14):1593-1600. doi: 10.1080/14796694.2026.2676559. Epub 2026 Jun 23. PubMed 42333826 ↗
  • Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gomez Caamano A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial. J Urol. 2026 May;215(5):512-525. doi: 10.1097/JU.0000000000004890. Epub 2025 Dec 9. PubMed 41364813 ↗
  • Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EPM, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. J Urol. 2026 Apr;215(4):396-407. doi: 10.1097/JU.0000000000004879. Epub 2025 Dec 5. PubMed 41349040 ↗
  • Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Kalac M, Sridharan S, Rosales M, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Wang F, Freedland SJ. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2026 Feb 5;394(6):563-575. doi: 10.1056/NEJMoa2510310. Epub 2025 Oct 19. PubMed 41124201 ↗
  • De Giorgi U, Freedland SJ, Rannikko A, Ramirez-Backhaus M, Villers A, Tarazi J, Tang Y, Haas GP, Rosales M, Shore ND. Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. Prostate Cancer Prostatic Dis. 2026 Mar;29(1):198-201. doi: 10.1038/s41391-025-00959-8. Epub 2025 Mar 26. PubMed 40140551 ↗
  • Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29. PubMed 38421252 ↗
  • Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29. PubMed 38421243 ↗
  • Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22. PubMed 38320501 ↗
  • Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND; EMBARK Study. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. PubMed 37851874 ↗
  • LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer. J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2. PubMed 37119051 ↗
  • Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, Haas GP, Shore ND. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 2021 Aug 12;11(8):e046588. doi: 10.1136/bmjopen-2020-046588. PubMed 34385241 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jan 2023, 97 months.

Results were first posted in Mar 2024, 1 year 1 month after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 97 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jul 2027, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2014
First posted
Dec 18, 2014
StartActual
Dec 17, 2014
Primary completionActual
Jan 31, 2023
CompletionEst.
Jul 30, 2027was Sep 2026
Results first posted
Mar 25, 2024
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 26, 2026
Sites
24 sites added, 24 sites removed
Show 24 added (14 Spain, 3 United Kingdom, 2 United States, 2 Austria, 1 Italy, 1 Poland, 1 Sweden)
  • Memorial Sloan Kettering Cancer Center Westchester · East White Plains, United States
  • Jefferson Urology Associates · Phiadelphia, United States
  • Ordensklinikum Linz GmbH · Linz, Austria
  • AKH - Medizinische Universität Wien · Vienna, Austria
  • Istituto Nazionale Tumori Fondazione G. Pascale/Oncologia Medica A · Naples, Italy
  • Kujawsko-Pomorskie Centrum Urologicznw Sp z o.o · Torun, Poland
  • Hospital del Mar · Barcelona, Spain
  • Hospital Clinic i Provincial de Barcelona, Dr. Antonio Alcaraz Asensio · Barcelona, Spain
  • Althaia, Xarxa Assistencial Universitària de Manresa · Manresa, Spain
  • Hospital Universitario Puerta del Mar · Cadiz, Spain
  • ICO Girona; Hospital Universitari de Girona Dr. Josep Trueta. Servicio de Oncologia · Girona, Spain
  • Complejo Hospitalario Universitario de Santiago · Santiago de Compostela, Spain
  • Hospital Universitario de La Princesa · Madrid, Spain
  • Hospital General Universitario Gregorio Maranon. Servicio de Oncologia. · Madrid, Spain
  • Centro Oncologico MD Anderson International Espana · Madrid, Spain
  • Hospital Universitario Ramon Y Cajal · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Complejo Hospitalario Universitario de Orense · Ourense, Spain
  • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
  • Instituto Valenciano de Oncologia IVO · Valencia, Spain
  • Akademiska Sjukhuset · Uppsala, Sweden
  • Royal Devon & Exeter Hospital · Wonford, United Kingdom
  • Royal Free Hospital · London, United Kingdom
  • The Royal Marsden NHS Foundation Trust · Sutton, United Kingdom
Show 24 removed
  • Memorial Sloan Kettering Cancer Center Westchester · Harrison, United States
  • Jefferson Urology Associates · Philadelphia, United States
  • Ordensklinikum Linz GmbH · Linz, Austria
  • AKH - Medizinische Universität Wien · Vienna, Austria
  • Istituto Nazionale Tumori Fondazione G. Pascale/Oncologia Medica A · Naples, Italy
  • Kujawsko-Pomorskie Centrum Urologicznw Sp z o.o · Torun, Poland
  • Althaia, Xarxa Assistencial Universitària de Manresa · Manresa, Spain
  • Complejo Hospitalario Universitario de Santiago · Santiago de Compostela, Spain
  • Hospital del Mar · Barcelona, Spain
  • Hospital Clinic i Provincial de Barcelona, Dr. Antonio Alcaraz Asensio · Barcelona, Spain
  • Hospital Universitario Puerta del Mar · Cadiz, Spain
  • ICO Girona; Hospital Universitari de Girona Dr. Josep Trueta. Servicio de Oncologia · Girona, Spain
  • Hospital Universitario de La Princesa · Madrid, Spain
  • Hospital General Universitario Gregorio Maranon. Servicio de Oncologia. · Madrid, Spain
  • Centro Oncologico MD Anderson International Espana · Madrid, Spain
  • Hospital Universitario Ramon Y Cajal · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Complejo Hospitalario Universitario de Orense · Ourense, Spain
  • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
  • Instituto Valenciano de Oncologia IVO · Valencia, Spain
  • Akademiska sjukhuset · Uppsala, Sweden
  • Royal Devon & Exeter Hospital · Wonford, United Kingdom
  • Royal Free Hospital · London, United Kingdom
  • The Royal Marsden NHS Foundation Trust · Sutton, United Kingdom
Oct 26, 2026
Study completion
Sep 19, 2026→Jul 30, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Posted results revised
    24 sites added, 24 sites removed
    Show 24 added (14 Spain, 3 United Kingdom, 2 United States, 2 Austria, 1 Italy, 1 Poland, 1 Sweden)
    • Memorial Sloan Kettering Cancer Center Westchester · East White Plains, United States
    • Jefferson Urology Associates · Phiadelphia, United States
    • Ordensklinikum Linz GmbH · Linz, Austria
    • AKH - Medizinische Universität Wien · Vienna, Austria
    • Istituto Nazionale Tumori Fondazione G. Pascale/Oncologia Medica A · Naples, Italy
    • Kujawsko-Pomorskie Centrum Urologicznw Sp z o.o · Torun, Poland
    • Hospital del Mar · Barcelona, Spain
    • Hospital Clinic i Provincial de Barcelona, Dr. Antonio Alcaraz Asensio · Barcelona, Spain
    • Althaia, Xarxa Assistencial Universitària de Manresa · Manresa, Spain
    • Hospital Universitario Puerta del Mar · Cadiz, Spain
    • ICO Girona; Hospital Universitari de Girona Dr. Josep Trueta. Servicio de Oncologia · Girona, Spain
    • Complejo Hospitalario Universitario de Santiago · Santiago de Compostela, Spain
    • Hospital Universitario de La Princesa · Madrid, Spain
    • Hospital General Universitario Gregorio Maranon. Servicio de Oncologia. · Madrid, Spain
    • Centro Oncologico MD Anderson International Espana · Madrid, Spain
    • Hospital Universitario Ramon Y Cajal · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Complejo Hospitalario Universitario de Orense · Ourense, Spain
    • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
    • Instituto Valenciano de Oncologia IVO · Valencia, Spain
    • Akademiska Sjukhuset · Uppsala, Sweden
    • Royal Devon & Exeter Hospital · Wonford, United Kingdom
    • Royal Free Hospital · London, United Kingdom
    • The Royal Marsden NHS Foundation Trust · Sutton, United Kingdom
    Show 24 removed
    • Memorial Sloan Kettering Cancer Center Westchester · Harrison, United States
    • Jefferson Urology Associates · Philadelphia, United States
    • Ordensklinikum Linz GmbH · Linz, Austria
    • AKH - Medizinische Universität Wien · Vienna, Austria
    • Istituto Nazionale Tumori Fondazione G. Pascale/Oncologia Medica A · Naples, Italy
    • Kujawsko-Pomorskie Centrum Urologicznw Sp z o.o · Torun, Poland
    • Althaia, Xarxa Assistencial Universitària de Manresa · Manresa, Spain
    • Complejo Hospitalario Universitario de Santiago · Santiago de Compostela, Spain
    • Hospital del Mar · Barcelona, Spain
    • Hospital Clinic i Provincial de Barcelona, Dr. Antonio Alcaraz Asensio · Barcelona, Spain
    • Hospital Universitario Puerta del Mar · Cadiz, Spain
    • ICO Girona; Hospital Universitari de Girona Dr. Josep Trueta. Servicio de Oncologia · Girona, Spain
    • Hospital Universitario de La Princesa · Madrid, Spain
    • Hospital General Universitario Gregorio Maranon. Servicio de Oncologia. · Madrid, Spain
    • Centro Oncologico MD Anderson International Espana · Madrid, Spain
    • Hospital Universitario Ramon Y Cajal · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Complejo Hospitalario Universitario de Orense · Ourense, Spain
    • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
    • Instituto Valenciano de Oncologia IVO · Valencia, Spain
    • Akademiska sjukhuset · Uppsala, Sweden
    • Royal Devon & Exeter Hospital · Wonford, United Kingdom
    • Royal Free Hospital · London, United Kingdom
    • The Royal Marsden NHS Foundation Trust · Sutton, United Kingdom
    Study completion Sep 19, 2026→Jul 30, 2027
    + 3 other changes: identifiers, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02319837
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Dec 18, 2014
Start date
Dec 17, 2014
Primary completion
Jan 31, 2023
Completion
Jul 30, 2027 (estimated)
Results posted
Mar 25, 2024
Last update
Oct 26, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enzalutamide · Luprolide acetate gel depot

Start the discussion